Sandoz Group AG (SDZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sandoz Group AG (SDZ) has a cash flow conversion efficiency ratio of 0.094x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF851.94 Million ≈ $1.08 Billion USD) by net assets (CHF9.03 Billion ≈ $11.41 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Sandoz Group AG for the company's overall valuation and market capitalisation.
Sandoz Group AG - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Sandoz Group AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sandoz Group AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sandoz Group AG ranked by their cash flow conversion efficiency. Explore SDZ operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samsung SDI
KO:006400
|
-0.010x |
|
Ares Management LP
NYSE:ARES
|
0.048x |
|
Yuanta Financial Holdings Co Ltd
TW:2885
|
-0.059x |
|
Hannover Rück SE
F:HNR1
|
0.128x |
|
DexCom Inc
NASDAQ:DXCM
|
0.178x |
|
Ameren Corp
NYSE:AEE
|
0.056x |
|
Heidelberg Materials AG
XETRA:HEI
|
0.169x |
|
TDK Corporation
F:TDKA
|
0.059x |
Annual Cash Flow Conversion Efficiency for Sandoz Group AG (2020–2025)
The table below shows the annual cash flow conversion efficiency of Sandoz Group AG from 2020 to 2025. View Sandoz Group AG (SDZ) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF9.38 Billion ≈ $11.87 Billion |
CHF1.59 Billion ≈ $2.02 Billion |
0.170x | +111.37% |
| 2024-12-31 | CHF8.16 Billion ≈ $10.32 Billion |
CHF656.00 Million ≈ $829.36 Million |
0.080x | +113.76% |
| 2023-12-31 | CHF8.65 Billion ≈ $10.94 Billion |
CHF325.31 Million ≈ $411.28 Million |
0.038x | -100.00% |
| 2022-12-31 | CHF77.14K ≈ $97.52K |
CHF1.17 Billion ≈ $1.48 Billion |
15142.076x | +9097643.39% |
| 2021-12-31 | CHF7.44 Billion ≈ $9.40 Billion |
CHF1.24 Billion ≈ $1.57 Billion |
0.166x | +10.25% |
| 2020-12-31 | CHF6.83 Billion ≈ $8.63 Billion |
CHF1.03 Billion ≈ $1.30 Billion |
0.151x | -- |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of ac… Read more